Intellia Therapeutics NTLA EBITDA
EBITDA at other companies
Other financials
Where this comes from
Calculated from Intellia Therapeutics’s reported figures.
The official record: Intellia Therapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →
Ask your AI about Intellia Therapeutics's ebitda.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI

Claude
Questions, answered.
- What is Intellia Therapeutics's EBITDA?
- Intellia Therapeutics (NTLA) reported EBITDA of -$98.33M in Q1 2026.
- How has Intellia Therapeutics's EBITDA changed year-over-year?
- Intellia Therapeutics's EBITDA increased by 16.9% year-over-year, from -$118.31M to -$98.33M.
- What is the long-term trend for Intellia Therapeutics's EBITDA?
- Over 4 years (2021 to 2025), Intellia Therapeutics's EBITDA has grown at a 13.4% compound annual growth rate (CAGR), from -$260.96M to -$431.21M.
- What does EBITDA mean?
- Earnings before interest, taxes, depreciation, and amortization — EBIT plus the D&A add-back from the cash-flow statement (EBITDA = EBIT + D&A). A proxy for cash earnings that strips out financing, tax, and non-cash charges.